

# Economic Burden of Charcot-Marie-Tooth Disease: A Systematic Review

Authors: Sukannya Mahapatra, Nidhun Kandoth, Vyshnavi Telukuntla, Amit Ahuja, Inderpreet Singh

# INTRODUCTION

- Charcot-Marie-Tooth disease (CMT) is one of the most prevalent hereditary neurological illnesses, affecting roughly 1 in 2,500 persons worldwide?
- It includes a range of genetically and clinically diverse disorders that are characterized by a persistent, increasing peripheral nerve impairment<sup>2</sup>
- The economic cost of CMT is still poorly understood, despite its widespread occurrence

# OBJECTIVES

This study aimed to identify the factors influencing the disease burden associated with CMT.

## METHODS

- A systematic literature search was conducted in the Embase® and Medline® databases in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to identify articles that reported data on healthcare costs and resource utilization related to CMT
- The search strategy employed relevant keywords to identify English-language studies focusing on the cost and resource utilization of patients with CMT
- Inclusion criteria were pre-defined, with a specific emphasis on studies reporting cost and healthcare resource utilization data for adult patients with CMT (Table 1)
- Two independent reviewers initially screened the titles and abstracts of all records identified through the electronic search. Subsequently, potentially relevant full-text articles were assessed by the same reviewers
- In cases of disagreement or uncertainty regarding inclusion, a third reviewer was consulted to reach a consensus

#### Table 1. Inclusion criteria

Population	Patients diagnosed with CMT
Population	Patients diagnosed with CMT
Outcomes	Cost and health-care resource use outcomes: <ul> <li>Direct and indirect cost components</li> <li>Total cost</li> <li>Healthcare resource cost</li> <li>Resource use data</li> <li>Societal costs</li> </ul>
Language	English
Study design	<ul> <li>Cost studies</li> <li>Resource use studies</li> <li>Cost/economic burden studies</li> <li>Economic evaluations reporting costs or resource use</li> <li>Budget impact analysis</li> <li>Cost-benefit analysis</li> <li>Cost-consequence analysis</li> <li>Cost-minimization analysis</li> <li>Cost-utility analysis</li> </ul>
Time frame	Inception-present (2024)
Language	English
Publication type	Full-text articles, conference abstracts
Intervention and comparator	No restriction
Country	No restriction

Keys: CMT, Charcot-Marie-Tooth disease ction was applied for the age of patients with CMT

# RESULTS


Among the 286 records screened, eight publications providing data across various geographies were included: Germany (1), England (1), EU and US (5), and the UK (1). Study flow diagram is provided in Figure 1

Figure 1. Study flow diagram




#### Affiliations: Lumanity, Gurugram, HR, India






Key: CMT, Charcot–Marie–Tooth disease. Note: Cost year 2015, Country: Germany. Source: Schorling et al. Neurology. 2019; 92(17):e2027-e37

Figure 3. Healthcare resources used by patients with CMT





- In Germany, the reported yearly total cost of illness was \$22,362 (Figure 2)<sup>3</sup> In the EU and the US, rehabilitative interventions and medication usage utilization rates ranged from 15.3% to 86.5% and 4.7% to 72.5%, respectively (Figure 3)<sup>2</sup> Orthotics/walking aids were utilized by 0.8% (EU and US) to 62.5% (England) of patients<sup>2,4</sup>
- Healthcare professional visits ranged from 36% (the UK) to 76% (Germany), with physiotherapists being the most frequently consulted, followed by neurologists<sup>5</sup>
- Furthermore, CMT was associated with considerable indirect costs. In the EU and US, high rates of disability-related unemployment (62%) and absenteeism from work (32%) were reported
- On average, patients missed 21 (the US) to 75 (France) workdays per year due to the disease<sup>7</sup> The majority of patients in Spain (96%), UK (78%), Germany (76%) and US (70%) reported that their work life is affected by CMT

Key: CMT, Charcot–Marie–Tooth disease. Source: Thomas et al. J Clin Neuromuscul Dis. 2022; 24(1):7-17.

## CONCLUSIONS

These findings underscore the considerable impact of CMT on healthcare resource utilization and productivity losses, highlighting the multifaceted challenges experienced by individuals affected by this progressive neurological condition.

### REFERENCES

1. Redmond et al. Neuromuscular disord. 2008; 18(8):619-25. 2. Thomas et al. J Clin Neuromuscul Dis. 2022; 24(1):7-17. 3. Schorling et al. Neurology. 2019; 92(17):e2027-e37. 4. Manivannan et al. Dev Med Child Neurol. 2021; 63(1). 5. Ziemssen et al. Value Health. 2019; 22:S847. 6. Ziemssen et al. Value Health. 2019; 22:S866-S7. 7. Thomas et al. J Neuromuscul Dis. 2022; 9



An electronic version of the poster can be viewed by scanning the QR code

### Poster presented at the 2024 ISPOR Europe; 17-20 November 2024; Barcelona, Spain.